IMRX
Income statement / Annual
Last year (2024), Immuneering Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Immuneering Corporation's net income was -$61.04 B.
See Immuneering Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$316,952.00 |
$2.08 M |
$2.31 M |
$1.92 M |
| Cost of Revenue |
$0.00
|
$764,138.00
|
$158,122.00
|
$1.15 M
|
$1.28 M
|
$1.22 M
|
| Gross Profit |
$0.00
|
-$764,138.00
|
$158,830.00
|
$926,888.00
|
$1.03 M
|
$696,739.00
|
| Gross Profit Ratio |
0
|
0
|
0.5
|
0.45
|
0.45
|
0.36
|
| Research and Development Expenses |
$47.96 B
|
$41.40 M
|
$36.27 M
|
$26.54 M
|
$15.00 M
|
$4.28 M
|
| General & Administrative Expenses |
$16.08 B
|
$16.76 M
|
$15.61 M
|
$8.27 M
|
$3.11 M
|
$2.71 M
|
| Selling & Marketing Expenses |
$0.00
|
-$511,871.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.08 B
|
$16.25 M
|
$15.61 M
|
$8.27 M
|
$3.11 M
|
$2.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$30,053.00
|
-$127,063.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$63.36 M
|
$57.65 M
|
$51.90 M
|
$34.81 M
|
$18.11 M
|
$6.99 M
|
| Cost And Expenses |
$0.00
|
$58.41 M
|
$52.06 M
|
$35.97 M
|
$19.39 M
|
$8.21 M
|
| Interest Income |
$2.59 M
|
$3.61 M
|
$1.01 M
|
$169,899.00
|
$42,656.00
|
$57,660.00
|
| Interest Expense |
$0.00
|
$0.00
|
$1.01 M
|
$0.00
|
$0.00
|
$351,302.00
|
| Depreciation & Amortization |
$0.00
|
$352,083.00
|
$796,793.00
|
$159,072.00
|
$79,305.00
|
$18,079.00
|
| EBITDA |
-$60.32 M |
-$58.06 M |
-$51.47 M |
-$33.68 M |
-$17.00 M |
-$7.34 M |
| EBITDA Ratio |
0
|
0
|
-162.38
|
-16.19
|
-7.36
|
-3.82
|
| Operating Income Ratio |
0
|
0
|
-163.26
|
-16.29
|
-7.39
|
-3.28
|
| Total Other Income/Expenses Net |
$3.03 B
|
$4.94 M
|
$1.23 M
|
$42,836.00
|
$42,656.00
|
-$1.42 M
|
| Income Before Tax |
-$61.04 B
|
-$53.47 M
|
-$50.51 M
|
-$33.84 M
|
-$17.04 M
|
-$7.71 M
|
| Income Before Tax Ratio |
0
|
0
|
-159.37
|
-16.27
|
-7.37
|
-4.02
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.23 M
|
-$307,485.00
|
-$84,336.00
|
$351,302.00
|
| Net Income |
-$61.04 B
|
-$53.47 M
|
-$49.28 M
|
-$33.54 M
|
-$17.04 M
|
-$8.06 M
|
| Net Income Ratio |
0
|
0
|
-155.49
|
-16.12
|
-7.37
|
-4.2
|
| EPS |
-2035.8 |
-1.88 |
-1.87 |
-1.27 |
-0.67 |
-0.32 |
| EPS Diluted |
-2035.8 |
-1.88 |
-1.87 |
-1.27 |
-0.67 |
-0.32 |
| Weighted Average Shares Out |
$29.98 M
|
$28.42 M
|
$26.39 M
|
$26.32 M
|
$25.51 M
|
$25.51 M
|
| Weighted Average Shares Out Diluted |
$29.98 M
|
$28.42 M
|
$26.39 M
|
$26.32 M
|
$25.51 M
|
$25.51 M
|
| Link |
|
|
|
|
|
|
